Myeloid-Derived Suppressor Cells and Clinical Outcomes in Children With COVID-19

• Egile Nagusiak: Katherine Bline (Egilea), Angel Andrews (Egilea), Melissa Moore-Clingenpeel (Egilea), Sara Mertz (Egilea), Fang Ye (Egilea), Victoria Best (Egilea), Rouba Sayegh (Egilea), Cristina Tomatis-Souverbielle (Egilea), Ana M. Quintero (Egilea), Zachary Maynard (Egilea), Rebecca Glowinski (Egilea), Asuncion Mejias (Egilea), Octavio Ramilo (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BackgroundAlthough children with COVID-19 account for fewer hospitalizations than adults, many develop severe disease requiring intensive care treatment. Critical illness due to COVID-19 has been associated with lymphopenia and functional immune suppression. Myeloid-derived suppressor cells (MDSCs)...